<?xml version='1.0' encoding='utf-8'?>
<document id="27336726"><sentence text="Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study." /><sentence text="Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC)" /><sentence text=" This study assessed the biological activity of ribociclib (LEE011; CDK4/6 inhibitor) plus letrozole compared with single-agent letrozole in the presurgical setting"><entity charOffset="91-100" id="DDI-PubMed.27336726.s3.e0" text="letrozole" /><entity charOffset="128-137" id="DDI-PubMed.27336726.s3.e1" text="letrozole" /><pair ddi="false" e1="DDI-PubMed.27336726.s3.e0" e2="DDI-PubMed.27336726.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27336726.s3.e0" e2="DDI-PubMed.27336726.s3.e1" /></sentence><sentence text="" /><sentence text="Postmenopausal women (N = 14) with resectable, HR+, human epidermal growth factor receptor 2-negative (HER2-) early BC were randomized 1:1:1 to receive 2" /><sentence text="5 mg/day letrozole alone (Arm 1), or with 400 or 600 mg/day ribociclib (Arm 2 or 3)"><entity charOffset="9-18" id="DDI-PubMed.27336726.s6.e0" text="letrozole" /><entity charOffset="60-70" id="DDI-PubMed.27336726.s6.e1" text="ribociclib" /><pair ddi="false" e1="DDI-PubMed.27336726.s6.e0" e2="DDI-PubMed.27336726.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27336726.s6.e0" e2="DDI-PubMed.27336726.s6.e1" /></sentence><sentence text=" Circulating tumor DNA and tumor biopsies were collected at baseline and, following 14 days of treatment, prior to or during surgery" /><sentence text=" The primary objective was to assess antiproliferative response per Ki67 levels in Arms 2 and 3 compared with Arm 1" /><sentence text=" Additional assessments included safety, pharmacokinetics, and genetic profiling" /><sentence text="" /><sentence text="Mean decreases in the Ki67-positive cell fraction from baseline were: Arm 1 69% (range 38-100%; n = 2), Arm 2 96% (range 78-100%; n = 6), Arm 3 92% (range 75-100%; n = 3)" /><sentence text=" Decreased phosphorylated Rb levels and CDK4, CDK6, CCND2, CCND3, and CCNE1 gene expression were observed following ribociclib treatment" /><sentence text=" Ribociclib and letrozole pharmacokinetic parameters were consistent with single-agent data"><entity charOffset="1-11" id="DDI-PubMed.27336726.s13.e0" text="Ribociclib" /><entity charOffset="16-25" id="DDI-PubMed.27336726.s13.e1" text="letrozole" /><pair ddi="false" e1="DDI-PubMed.27336726.s13.e0" e2="DDI-PubMed.27336726.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27336726.s13.e0" e2="DDI-PubMed.27336726.s13.e1" /></sentence><sentence text=" The ribociclib plus letrozole combination was well tolerated, with no Grade 3/4 adverse events over the treatment"><entity charOffset="21-30" id="DDI-PubMed.27336726.s14.e0" text="letrozole" /></sentence><sentence text="" /><sentence text="The results suggest absence of a drug-drug interaction between ribociclib and letrozole and indicate ribociclib plus letrozole may reduce Ki67 expression in HR+, HER2- BC (NCT01919229)"><entity charOffset="63-73" id="DDI-PubMed.27336726.s16.e0" text="ribociclib" /><entity charOffset="78-87" id="DDI-PubMed.27336726.s16.e1" text="letrozole" /><entity charOffset="117-126" id="DDI-PubMed.27336726.s16.e2" text="letrozole" /><pair ddi="false" e1="DDI-PubMed.27336726.s16.e0" e2="DDI-PubMed.27336726.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27336726.s16.e0" e2="DDI-PubMed.27336726.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27336726.s16.e0" e2="DDI-PubMed.27336726.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27336726.s16.e1" e2="DDI-PubMed.27336726.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27336726.s16.e1" e2="DDI-PubMed.27336726.s16.e2" /></sentence><sentence text="" /></document>